# Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI

> **NCT01893151** · PHASE4 · UNKNOWN · sponsor: **Jiangsu Simcere Pharmaceutical Co., Ltd.** · enrollment: 200 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Iguratimod
- **DRUG:** Iguratimod placebo

## Key facts

- **NCT ID:** NCT01893151
- **Lead sponsor:** Jiangsu Simcere Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2012-07
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2014-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01893151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01893151, "Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01893151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*